The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.

Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a significant weight reduction compared with placebo, according to top-line results from a phase 1b/2a trial.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side effects.

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications. Experts break down the findings.

The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight.In report published in Nature Medicine,

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.